ArticleFrontiers in veterinary science2019
The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs.
Article in Frontiers in veterinary science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Advances and Challenges in the Diagnosis of Vector-Borne Protozoal Infections in Veterinary Medicine.Pathogens (Basel, Switzerland) · 2026Review
- Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis.PLoS neglected tropical diseases · 2025Article
- Synthetic Peptides Selected by Immunoinformatics as Potential Tools for the Specific Diagnosis of Canine Visceral Leishmaniasis.Microorganisms · 2024Article
- Use of Antigen Combinations to Address ComplexMicroorganisms · 2022Article
- Antibodies elicited by the CaniLeish® vaccine: long-term clinical follow-up study of dogs in Spain.Parasitology research · 2021Article
- Visceral Dissemination of Mucocutaneous Leishmaniasis in a Kidney Transplant Recipient.Pathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine leishmaniosis (CanL) prevention in the Mediterranean basin is considered essential to stop human zoonotic visceral leishmaniasis. In this context, vaccination of dogs is expected to have a significant impact in disease control. CaniLeish® (Virbac Animal Health) is one of a few CanL vaccines that are at this moment licensed in Europe. This vaccine contains purified excreted-secreted proteins of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.